<DOC>
	<DOCNO>NCT01564862</DOCNO>
	<brief_summary>The purpose study evaluate effect Lu AA21004 , daily ( QD ) , cognitive dysfunction patient major depressive disorder .</brief_summary>
	<brief_title>Efficacy Lu AA21004 Cognitive Dysfunction Major Depressive Disorder</brief_title>
	<detailed_description>Lu AA21004 codevelopment Takeda Global Research &amp; Development Center , Inc. H. Lundbeck A/S treatment MDD . This study consist screen period within 10 day Baseline Visit follow 8-week double-blind treatment period one-week taper period .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . The participant recurrent MDD primary diagnosis accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criterion ( classification code 296.3x ) . The current MDE confirm use Mini International Neuropsychiatric Interview ( MINI ) V6.0.0 . 4 . The participant receive prescribed treatment previous episode depression . 5 . The participant MADRS total score ≥26 screen baseline visit . 6 . Participant report subjective cognitive dysfunction ( difficulty concentrating , slow thinking , difficulty learn new thing remember thing ) . 7 . The report duration current major depressive episode ( MDE ) least 3 month 8 . The participant man woman 18 65 year old , inclusive . 9 . A female participant childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception signing inform consent throughout duration study 30 day completion study . 1 . The participant previously participate study . 2 . The participant history severe drug allergy hypersensitivity , know hypersensitivity excipients investigational medicinal product ( IMP ) . 3 . The participant know hypersensitivity duloxetine . 4 . The participant hereditary problem fructose intolerance , glucosegalactose malabsorption , sucroseisomaltase insufficiency . 5 . The participant immediate family member , study site employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) may consent duress . 6 . The participant score ≥70 DSST ( number correct ) Baseline Visit . 7 . The participant , opinion investigator , able complete neuropsychological test validly Baseline Visit . 8 . If female , participant pregnant lactate intend become pregnant , , within 30 day participate study ; intend donate ova time period . 9 . The participant 1 following : 1 . Any current psychiatric disorder MDD define DSMIVTR ( assess MINI Version 6.0.0 ) . 2 . Current history attention deficit hyperactivity disorder ( ADHD ) , pervasive developmental disorder , manic hypomanic episode , schizophrenia , psychotic disorder , include major depression psychotic feature , mental retardation , organic mental disorder , mental disorder due general medical condition define DSMIVTR . 3 . Current diagnosis alcohol substance abuse dependence ( exclude nicotine caffeine ) define DSMIVTR sustain full remission least 2 year prior Screening . ( Participant must also negative urine drug screen prior Baseline ) . 4 . Presence history clinically significant neurological disorder ( include epilepsy ) . 5 . Neurodegenerative disorder ( Alzheimer 's disease , Parkinson 's disease , multiple sclerosis , Huntington 's disease , etc ) . 6 . Any DSMIV Axis II disorder might compromise study . 10 . The participant disorder treatment take priority treatment MDD likely interfere study treatment impair treatment compliance . 11 . The participant physical , cognitive , language impairment severity adversely affect validity data derive neuropsychological test . 12 . The participant diagnose read disability ( dyslexia ) . 13 . The participant significant risk suicide accord investigator 's clinical judgment score ≥5 item 10 ( suicidal thought ) MADRS make suicide attempt previous 6 month . 14 . The participant , opinion investigator , pose risk harm others . 15 . The participant initiate formal cognitive behavioral therapy , systemic psychotherapy within less 6 month study screening , plan initiate therapy study . 16 . The participant receive electroconvulsive therapy , vagal nerve stimulation , repetitive transcranial magnetic stimulation within 6 month prior Screening . 17 . The current depressive symptom consider investigator resistant 2 adequate antidepressant treatment least 6 week duration recommend dose . 18 . The participant history moderate severe head trauma ( example , loss consciousness 1 hour ) neurological disorder systemic medical disease , opinion investigator , likely affect central nervous system function . 19 . The participant previous history cancer remission le 5 year prior first dose investigational drug . This criterion include participant basal cell stage I squamous cell carcinoma skin . 20 . The participant clinically significant unstable illness , example , hepatic impairment renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological , rheumatologic , immunologic , infectious , skin subcutaneous tissue disorder , metabolic disturbance . Note : For purpose protocol , follow condition consider unstable due potential impact assessment MDD response and/or cognitive status : pain disorder , chronic fatigue syndrome , fibromyalgia , obstructive sleep apnea , know case HIV , HBV , HCV 21 . The participant known history currently increase intraocular pressure risk acute narrowangle glaucoma . 22 . The participant require take excluded medication anticipate participant require treatment least 1 disallow concomitant medication study evaluation period specify Excluded Medications Section . 23 . The participant receive investigational compound &lt; 30 day Screening 5 halflives prior Screening . 24 . The participant clinically significant abnormal vital sign determine investigator . 25 . The subject thyroid stimulate hormone ( TSH ) outside normal range Screening Visit . Note : If TSH value outside normal range , free T4 obtain . Subjects elevate TSH normal T4 ( i.e . subclinical hypothyroidism ) exclude . For subject thyroid hormone replacement therapy , low TSH normal T4 , eligible participate study clinical symptom hypothyroidism . 26 . The participant 1 laboratory value outside normal range , base blood urine sample take Screening Visit , consider investigator clinically significant ; participant follow value Screening Visit : 1 . A serum creatinine value &gt; 1.5 time upper limit normal ( ×ULN ) . 2 . A total serum total bilirubin value &gt; 1.5×ULN . 3 . A serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) value &gt; 2×ULN . 27 . The participant abnormal electrocardiogram ( ECG ) determine central reader confirm clinically significant investigator . 28 . The participant disease take medication , opinion investigator , could interfere assessment safety , tolerability , efficacy . 29 . The participant , opinion investigator , unlikely comply clinical study protocol unsuitable reason . 30 . The participant previously expose LuAA21004 compound . 31 . The participant history lack response previous adequate treatment duloxetine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>